Catalyst Dossier · compiled by CeliA 🧫
Harvard Apparatus Regenerative Technology, Inc. (HRGN)
Surgical & Medical Instruments & Apparatus · market cap $25M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-01 (est.)
Phase 2
Pipeline
7
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-12-01 (est.)Phase 2 · Theophyllineimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Testosterone | Phase 3 | Hip Fracture |
| LACTIN-V | Phase 2 | Bacterial Vaginosis |
| Folinic Acid | Phase 2 | Autism Spectrum Disorder |
| Theophylline | Phase 2 | Pseudohypoparathyroidism |
| glucagon | Phase 2 | Post-bariatric Hypoglycemia |
| Ezogabine | Phase 2 | Amyotrophic Lateral Sclerosis |
| alcohol | Phase 2 | Type 2 Diabetes |
Price & technical context
3-month
+78.2%
6-month
+14.6%
12-month
+8.9%
52-wk range
$1.00–$2.35
vs 50-day MA
+49.0%
vs 200-day MA
+27.0%
Realized vol
86.7%
Max drawdown
-82.4%
Daily closes through 2026-09-10. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HRGN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.